{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:11:35Z","timestamp":1794363095051,"version":"4.9.0"},"reference-count":94,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ACI\/Schwenn Family Professorship","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}]},{"name":"ACI\/Schwenn Family Professorship","award":["R37 CA226526"],"award-info":[{"award-number":["R37 CA226526"]}]},{"name":"ACI\/Schwenn Family Professorship","award":["R01 CA272855"],"award-info":[{"award-number":["R01 CA272855"]}]},{"name":"JD Fluno Family Colorectal Cancer Precision Medicine Program","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}]},{"name":"JD Fluno Family Colorectal Cancer Precision Medicine Program","award":["R37 CA226526"],"award-info":[{"award-number":["R37 CA226526"]}]},{"name":"JD Fluno Family Colorectal Cancer Precision Medicine Program","award":["R01 CA272855"],"award-info":[{"award-number":["R01 CA272855"]}]},{"DOI":"10.13039\/100007923","name":"University of Wisconsin Carbone Cancer Center","doi-asserted-by":"publisher","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100007923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007923","name":"University of Wisconsin Carbone Cancer Center","doi-asserted-by":"publisher","award":["R37 CA226526"],"award-info":[{"award-number":["R37 CA226526"]}],"id":[{"id":"10.13039\/100007923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007923","name":"University of Wisconsin Carbone Cancer Center","doi-asserted-by":"publisher","award":["R01 CA272855"],"award-info":[{"award-number":["R01 CA272855"]}],"id":[{"id":"10.13039\/100007923","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NCI","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}]},{"name":"NIH\/NCI","award":["R37 CA226526"],"award-info":[{"award-number":["R37 CA226526"]}]},{"name":"NIH\/NCI","award":["R01 CA272855"],"award-info":[{"award-number":["R01 CA272855"]}]},{"name":"V Foundation","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}]},{"name":"V Foundation","award":["R37 CA226526"],"award-info":[{"award-number":["R37 CA226526"]}]},{"name":"V Foundation","award":["R01 CA272855"],"award-info":[{"award-number":["R01 CA272855"]}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Phosphatidylinositol-3-kinase (PI3K)\/AKT\/mammalian target of rapamycin (MTOR) pathway hyperactivation is seen in a multitude of malignancies. Due to the importance of this pathway in numerous critical cellular functions, preclinical and clinical investigations have aimed to target this pathway as an anti-cancer therapeutic strategy. This has led to the development of PI3K, AKT, and MTOR inhibitors for use in cancer patients, leading to multiple FDA approvals over the past decade. In this review, we outline therapeutic targets in PI3K\/AKT\/MTOR signaling in solid tumors, the current state of using inhibitors of this pathway to treat patients whose cancers possess activating mutations in PIK3CA, AKT1\/2, or MTOR, and exciting new inhibitors that are entering clinical trials.<\/jats:p>","DOI":"10.3390\/biomedicines13061319","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T08:12:47Z","timestamp":1748419967000},"page":"1319","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies"],"prefix":"10.3390","volume":"13","author":[{"given":"Alexa E.","family":"Schmitz","sequence":"first","affiliation":[{"name":"McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin, Madison, WI 53705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1929-8121","authenticated-orcid":false,"given":"Shirsa","family":"Udgata","sequence":"additional","affiliation":[{"name":"McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin, Madison, WI 53705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6335-7782","authenticated-orcid":false,"given":"Katherine A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Madison, WI 53705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin A.","family":"Deming","sequence":"additional","affiliation":[{"name":"McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin, Madison, WI 53705, USA"},{"name":"University of Wisconsin Carbone Cancer Center, Madison, WI 53705, USA"},{"name":"Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: Divergent roles of isoforms, modes of activation, and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: Mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Porta, C., Paglino, C., and Mosca, A. (2014). Targeting PI3K\/Akt\/mTOR Signaling in Cancer. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00064"},{"key":"ref_5","unstructured":"(2024, April 17). The Structure of PI3K. Available online: https:\/\/proteopedia.org\/wiki\/index.php\/The_Structure_of_PI3K."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Leontiadou, H., Galdadas, I., Athanasiou, C., and Cournia, Z. (2018). Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-27044-6"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1016\/j.jmb.2020.09.002","article-title":"Structural Features that Distinguish Inactive and Active PI3K Lipid Kinases","volume":"432","author":"Zhang","year":"2020","journal-title":"J. Mol. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.4143\/crt.2019.497","article-title":"PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane\u2013Based Neoadjuvant Chemotherapy","volume":"52","author":"Guo","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hemmings, B.A., and Restuccia, D.F. (2012). PI3K-PKB\/Akt Pathway. Cold Spring Harb. Perspect. Biol., 4.","DOI":"10.1101\/cshperspect.a011189"},{"key":"ref_10","first-page":"1517","article-title":"Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine","volume":"14","author":"Coleman","year":"2021","journal-title":"Pharmacogenom. Pers. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"112820","DOI":"10.1016\/j.ejmech.2020.112820","article-title":"Research progress of mTOR inhibitors","volume":"208","author":"Chen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.molcel.2010.05.017","article-title":"Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition","volume":"38","author":"Yip","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jbior.2019.03.003","article-title":"Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship","volume":"72","author":"Wainwright","year":"2019","journal-title":"Adv. Biol. Regul."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/s41467-022-29655-0","article-title":"Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors","volume":"13","author":"Savill","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.4161\/cc.10.14.16586","article-title":"mTOR complex 2 signaling and functions","volume":"10","author":"Oh","year":"2011","journal-title":"Cell Cycle"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.18632\/oncotarget.2742","article-title":"The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy","volume":"6","author":"Ehrhardt","year":"2015","journal-title":"Oncotarget"},{"key":"ref_17","first-page":"2035","article-title":"PI3K inhibitor D-116883 is effective in in vitro models of ovarian cancer","volume":"32","author":"Honig","year":"2012","journal-title":"Anticancer. Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Destefanis, R.A., Schmitz, A.E., Steimle, A.K., Payne, S.N., Sha, G.C., Olson, A.M., Cornelio, A., Lippert, A.E.L., Kraus, S.G., and Johnson, K.A. (2025). BCL-2 Family Inhibition Enhances mTORC1\/2 Inhibition in PIK3CA-Mutant Colorectal Cancer. Mol. Cancer Ther., OF1\u2013OF14.","DOI":"10.1158\/1535-7163.MCT-24-1096"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Udgata, S., Stoecker, J.N., Shen, X., Pasch, C.A., and Deming, D.A. (2025). Co-existent PIK3CA and ARID1A mutations lead to enhanced sensitivity to PI3K inhibition through PUMA induction by FOXO3a and p53\/p21. Proceedings of the American Association for Cancer Research Annual Meeting 2025, Part 1 (Regular Abstracts), Chicago, IL, USA, 25\u201330 April 2025, AACR.","DOI":"10.1158\/1538-7445.AM2025-371"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1541-7786.MCR-16-0256","article-title":"Dual PI3K\/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations","volume":"15","author":"Foley","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1158\/1535-7163.MCT-18-0510","article-title":"MTORC1\/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers","volume":"18","author":"Fricke","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11912-010-0091-6","article-title":"Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer","volume":"12","author":"Cleary","year":"2010","journal-title":"Curr. Oncol. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1158\/1535-7163.763.3.7","article-title":"Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling","volume":"3","author":"Ihle","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","article-title":"Picking the Point of Inhibition: A Comparative Review of PI3K\/AKT\/mTOR Pathway Inhibitors","volume":"13","author":"Dienstmann","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mishra, R., Patel, H., Alanazi, S., Kilroy, M.K., and Garrett, J.T. (2021). PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073464"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.21.01648","article-title":"Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F","volume":"40","author":"Damodaran","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/bloodadvances.2020002910","article-title":"Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma","volume":"5","author":"Panayiotidis","year":"2021","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e886","DOI":"10.1016\/j.clml.2021.06.021","article-title":"Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib with Rituximab-Based Immunochemotherapy in Patients with Relapsed Indolent B-cell Lymphoma","volume":"21","author":"Matasar","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2014.12.019","article-title":"Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma","volume":"136","author":"Matulonis","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","article-title":"First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan\u2013Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors","volume":"21","author":"Sarker","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"TPS1148","DOI":"10.1200\/jco.2014.32.15_suppl.tps1148","article-title":"TBCRC028: A phase Ib\/II trial of GDC-0941 (a PI3K inhibitor) in combination with cisplatin in metastatic androgen receptor-negative triple-negative breast cancer (TNBC)","volume":"32","author":"Abramson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13058-018-1015-x","article-title":"A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer","volume":"20","author":"Cresta","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_33","unstructured":"(2024, April 29). Sonolisib, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Sonolisib."},{"key":"ref_34","first-page":"1270","article-title":"Phase II study of PX-866 in recurrent glioblastoma","volume":"17","author":"Pitz","year":"2015","journal-title":"Neuro-Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.clgc.2019.03.005","article-title":"A Phase II Study of PX-866 in Patients with Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group study","volume":"17","author":"Hotte","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_36","unstructured":"(2024, May 01). FDA Approves Alpelisib for Metastatic Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-alpelisib-metastatic-breast-cancer."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_38","unstructured":"(2024, May 01). Alpelisib (Oral Route). Available online: https:\/\/www.mayoclinic.org\/drugs-supplements\/alpelisib-oral-route\/description\/drg-20465046."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_40","unstructured":"(2024, May 03). FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative, Advanced Breast Cancer. Available online: https:\/\/www.onclive.com\/view\/fda-approves-inavolisib-plus-palbociclib-fulvestrant-for-endocrine-resistant-pik3ca-mutated-hr-her2-advanced-breast-cancer."},{"key":"ref_41","unstructured":"(2024, May 02). Dactolisib, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Dactolisib."},{"key":"ref_42","first-page":"713","article-title":"A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours","volume":"36","author":"Fazio","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Netland, I.A., F\u00f8rde, H.E., Sleire, L., Leiss, L., Rahman, M.A., Skeie, B.S., Gjerde, C.H., Enger, P.\u00d8., and Goplen, D. (2016). Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2712-4"},{"key":"ref_44","unstructured":"(2024, May 04). Apitolisib, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Apitolisib."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2015.64.8808","article-title":"Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K\/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients with Metastatic Renal Cell Carcinoma","volume":"34","author":"Powles","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","article-title":"Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors","volume":"22","author":"Dolly","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/cncr.32677","article-title":"Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway","volume":"126","author":"Rubinstein","year":"2020","journal-title":"Cancer"},{"key":"ref_48","unstructured":"(2024, May 04). Phase II Trial of LY3023414, a PI3K\/mTOR Inhibitor, in Patients with Recurrent Osteosarcoma. Available online: https:\/\/www.dana-farber.org\/clinical-trials\/18-115."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-21-2326","article-title":"Phase Ib\/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"28","author":"Sweeney","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Browne, I.M., and Okines, A.F.C. (2024). Resistance to Targeted Inhibitors of the PI3K\/AKT\/mTOR Pathway in Advanced Oestrogen-Receptor Positive Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16122259"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1038\/oncsis.2013.46","article-title":"Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer","volume":"2","author":"Huw","year":"2013","journal-title":"Oncogenesis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1158\/0008-5472.CAN-15-2201","article-title":"Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110\u03b2","volume":"76","author":"Nakanishi","year":"2016","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccell.2016.06.004","article-title":"PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K\u03b1 Inhibition","volume":"30","author":"Castel","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2020006765","article-title":"Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia","volume":"138","author":"Murali","year":"2021","journal-title":"Blood"},{"key":"ref_55","unstructured":"(2024, May 04). A Study of LOXO-783 in Patients with Breast Cancer\/Other Solid Tumors, Available online: https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2022-04290."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1158\/2159-8290.CD-23-0396","article-title":"STX-478, a Mutant-Selective, Allosteric PI3K\u03b1 Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3K\u03b1-Mutant Xenografts","volume":"13","author":"Buckbinder","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/2159-8290.CD-23-0944","article-title":"Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3K\u03b1 Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia","volume":"14","author":"Varkaris","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_58","unstructured":"(2024, May 04). RLY-2608 Shows Broad Therapeutic Potential in PIK3CA-Mutant Solid Tumors. Available online: https:\/\/www.onclive.com\/view\/rly-2608-shows-broad-therapeutic-potential-in-pik3ca-mutant-solid-tumors."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41416-024-02614-w","article-title":"Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer","volume":"130","author":"Eberlin","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1158\/0008-5472.CAN-18-2861","article-title":"Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer","volume":"79","author":"Weisner","year":"2019","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","article-title":"MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo","volume":"9","author":"Hirai","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.eururo.2014.08.053","article-title":"High Efficacy of Combination Therapy Using PI3K\/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models","volume":"67","author":"Marques","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1042\/BST20190777","article-title":"Inhibitors in AKTion: ATP-competitive vs allosteric","volume":"48","author":"Lazaro","year":"2020","journal-title":"Biochem. Soc. Trans."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.breast.2022.03.018","article-title":"The emerging role of capivasertib in breast cancer","volume":"63","author":"Andrikopoulou","year":"2022","journal-title":"Breast J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/jamaoncol.2020.6741","article-title":"Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor","volume":"7","author":"Kalinsky","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_67","unstructured":"(2024, May 04). FDA Approves Capivasertib with Fulvestrant for Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-capivasertib-fulvestrant-breast-cancer."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1021\/jm301024w","article-title":"Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors","volume":"55","author":"Blake","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0959-8049(22)00824-3","article-title":"Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K","volume":"174","author":"Kalinsky","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","article-title":"AKT as a Therapeutic Target for Cancer","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1158\/1078-0432.CCR-14-0868","article-title":"Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers","volume":"20","author":"Yap","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3577","article-title":"A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors","volume":"15","author":"Hudis","year":"2013","journal-title":"Breast Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1021\/acsmedchemlett.9b00548","article-title":"Spotlight on AKT: Current Therapeutic Challenges","volume":"11","author":"Landel","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1002\/ijc.28579","article-title":"Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts","volume":"134","author":"Ingels","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/erc.0.0080249","article-title":"mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer","volume":"8","author":"Yu","year":"2001","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","volume":"68","author":"Serra","year":"2008","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5732\/cjc.011.10281","article-title":"Current development of the second generation of mTOR inhibitors as anticancer agents","volume":"32","author":"Zhou","year":"2013","journal-title":"Chin. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.yexcr.2008.11.007","article-title":"The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma","volume":"315","author":"Baumann","year":"2009","journal-title":"Exp. Cell Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1158\/1535-7163.MCT-09-0160","article-title":"NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas","volume":"8","author":"Liu","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1158\/1078-0432.CCR-09-0816","article-title":"NVP-BEZ235 as a new therapeutic option for sarcomas","volume":"16","author":"Manara","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res."},{"key":"ref_82","unstructured":"(2024, May 03). Nanoparticle Albumin-Bound mTOR Inhibitor Gets Priority Review for Ultra-Rare Sarcoma. Available online: https:\/\/www.empr.com\/home\/news\/drugs-in-the-pipeline\/fda-priority-review-fyarro-nda-advanced-malignant-perivascular-epithelioid-cell-tumor."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1186\/2001-1326-1-29","article-title":"Rapamycin and mTOR: A serendipitous discovery and implications for breast cancer","volume":"1","author":"Seto","year":"2012","journal-title":"Clin. Transl. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1634\/theoncologist.2009-0178","article-title":"FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma","volume":"15","author":"Kwitkowski","year":"2010","journal-title":"Oncologist"},{"key":"ref_85","unstructured":"(2024, May 03). FDA approves Lenvatinib\/Everolimus for Advanced RCC. Available online: https:\/\/www.onclive.com\/view\/fda-approves-lenvatinibeverolimus-for-advanced-rcc."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0959-8049(22)00870-X","article-title":"Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131)-Phase 2 Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations: Sub-protocol EAY131-M","volume":"174","author":"Hays","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/157015912804499537","article-title":"mTOR Inhibitors in Tuberous Sclerosis Complex","volume":"10","author":"Curatolo","year":"2012","journal-title":"Curr. Neuropharmacol."},{"key":"ref_88","unstructured":"Pelosci, A. (2024, May 03). FDA Approves Nab-Sirolimus for Locally Advanced Unresectable or Metastatic PEComa. Available online: https:\/\/www.cancernetwork.com\/view\/fda-approves-nab-sirolimus-for-locally-advanced-unresectable-or-metastatic-pecoma."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Mao, B., Zhang, Q., Ma, L., Zhao, D.S., Zhao, P., and Yan, P. (2022). Overview of Research into mTOR Inhibitors. Molecules, 27.","DOI":"10.3390\/molecules27165295"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nature17963","article-title":"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor","volume":"534","author":"Okaniwa","year":"2016","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/sj.bjc.6604938","article-title":"The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer","volume":"100","author":"Diaz","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2017.01.014","article-title":"A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma","volume":"31","author":"Fan","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","article-title":"Recent advances and limitations of mTOR inhibitors in the treatment of cancer","volume":"22","author":"Ali","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/cas.14395","article-title":"Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma","volume":"111","author":"Kuroshima","year":"2020","journal-title":"Cancer Sci."}],"updated-by":[{"DOI":"10.3390\/biomedicines13112627","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000}}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/6\/1319\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T02:48:20Z","timestamp":1761706100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/6\/1319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":94,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["biomedicines13061319"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13061319","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}